835 related articles for article (PubMed ID: 33578831)
1. Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors.
Kalhotra P; Chittepu VCSR; Osorio-Revilla G; Gallardo-Velazquez T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33578831
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
3. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
4. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
[TBL] [Abstract][Full Text] [Related]
5. Exploring the anti-SARS-CoV-2 main protease potential of FDA approved marine drugs using integrated machine learning templates as predictive tools.
Attiq N; Arshad U; Brogi S; Shafiq N; Imtiaz F; Parveen S; Rashid M; Noor N
Int J Biol Macromol; 2022 Nov; 220():1415-1428. PubMed ID: 36122771
[TBL] [Abstract][Full Text] [Related]
6. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL
Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH
J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061
[TBL] [Abstract][Full Text] [Related]
8. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study.
Das S; Sarmah S; Lyndem S; Singha Roy A
J Biomol Struct Dyn; 2021 Jun; 39(9):3347-3357. PubMed ID: 32362245
[TBL] [Abstract][Full Text] [Related]
9. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some
Amin SA; Ghosh K; Gayen S; Jha T
J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618
[TBL] [Abstract][Full Text] [Related]
10. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
[TBL] [Abstract][Full Text] [Related]
11. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
Molecules; 2020 May; 25(11):. PubMed ID: 32485894
[TBL] [Abstract][Full Text] [Related]
12. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
[TBL] [Abstract][Full Text] [Related]
13. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.
Isgrò C; Sardanelli AM; Palese LL
Viruses; 2021 Jan; 13(1):. PubMed ID: 33451132
[TBL] [Abstract][Full Text] [Related]
14. High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2.
Olubiyi OO; Olagunju M; Keutmann M; Loschwitz J; Strodel B
Molecules; 2020 Jul; 25(14):. PubMed ID: 32668701
[TBL] [Abstract][Full Text] [Related]
15. [Development of antiviral drugs based on inhibitors of the SARS-COV-2 main protease].
Sulimov AV; Shikhaliev KS; Pyankov OV; Shcherbakov DN; Chirkova VY; Ilin IS; Kutov DC; Tashchilova AS; Krysin MY; Krylskiy DV; Stolpovskaya NV; Volosnikova EA; Belenkaya SV; Sulimov VB
Biomed Khim; 2021 May; 67(3):259-267. PubMed ID: 34142533
[TBL] [Abstract][Full Text] [Related]
16. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.
Jiménez-Alberto A; Ribas-Aparicio RM; Aparicio-Ozores G; Castelán-Vega JA
Comput Biol Chem; 2020 Oct; 88():107325. PubMed ID: 32623357
[TBL] [Abstract][Full Text] [Related]
17. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.
Kumar D; Kumari K; Vishvakarma VK; Jayaraj A; Kumar D; Ramappa VK; Patel R; Kumar V; Dass SK; Chandra R; Singh P
J Biomol Struct Dyn; 2021 Aug; 39(13):4671-4685. PubMed ID: 32567995
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.
Gimeno A; Mestres-Truyol J; Ojeda-Montes MJ; Macip G; Saldivar-Espinoza B; Cereto-Massagué A; Pujadas G; Garcia-Vallvé S
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471205
[TBL] [Abstract][Full Text] [Related]
19. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
[TBL] [Abstract][Full Text] [Related]
20. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.
Forrestall KL; Burley DE; Cash MK; Pottie IR; Darvesh S
Chem Biol Interact; 2021 Feb; 335():109348. PubMed ID: 33278462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]